KRAS and non-small cell lung carcinoma: Recently, G12C mutation gained considerable interest after the FDA approved the use of sotorasib, a KRAS-G12C protein inhibitor, in metastatic non-small cell lung carcinoma (NSCLC) with G12C mutation.